Phosphoric Acid

Phosphoric Acid

SCHEMBL2549258

O=P([O-])(O)O.O=P([O-])([O-])[O-].[Ca+2].[Mg+2]

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC34A1 Q06495 1/20 0.67
LMNA P02545 2/20 0.38
KDM4E B2RXH2 2/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 1/20 0.37
CA2 P00918 1/20 0.36
TYMS P04818 1/20 0.35
FDPS P14324 2/20 0.33
MMP2 P08253 1/20 0.31
THRB P10828 1/20 0.31
MAPK1 P28482 1/20 0.31
HSD17B10 Q99714 1/20 0.31
BLM P54132 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL28993323 0.96 SLC34A1 (0.61) SLC34A1LMNAKDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL298141 0.95 SLC34A1 (0.73) SLC34A1LMNAKDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL28993322 0.92 SLC34A1 (0.57) SLC34A1LMNAKDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL28585359 0.91 SLC34A1 (0.67) SLC34A1LMNAKDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL9008718 0.91 SLC34A1 (0.67) SLC34A1LMNAKDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL8508247 0.91 SLC34A1 (0.67) SLC34A1LMNAKDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL11867838 0.91 SLC34A1 (0.67) SLC34A1LMNAKDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL29828900 0.91 SLC34A1 (0.67) SLC34A1LMNAKDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL7163381 0.91 SLC34A1 (0.67) SLC34A1LMNAKDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL3850640 0.91 SLC34A1 (0.67) SLC34A1LMNAKDM4ECYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120164216-A1 PHARMACEUTICAL COMPOSITION OF DULOXETINE OR PHARMACEUTICALLY MATE SANJAY (IN) 2012-06-28 US claimed
WO-2010150219-A1 PHARMACEUTICAL COMPOSITION OF DULOXETINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF WOCKHARDT RESEARCH CENTRE (IN) 2010-12-29 WO claimed
US-6699885-B2 Treating gastrointestinal disorders by administering solid oral dosage form of proton pump inhibitor and buffer; buffer inhibits degradation of the proton pump inhibitor by gastric acid; bioavailability THE CURATORS OF THE UNIVERSITY OF MISSOURI 2004-03-02 US claimed
US-4223115-A ADDITION POLYMERIZABLE SYSTEM CONTAINING REDOX COUPLE CATALYST AND PHOSPHORUS COMPOUND LORD CORPORATION (US) 1980-09-16 US claimed
US-12376612-B2 Edible concentrate comprising microfibrillated cellulose CONOPCO INC. (US) 2025-08-05 US disclosed
US-12042302-B2 Enhanced ingestible event indicators and methods for making and using the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-07-23 US disclosed
EP-4164408-A1 DYE FOR FOODS, NUTRITIONAL SUPPLEMENTS, AND COSMETIC OR PHARMACEUTICAL PRODUCTS Döhler GmbH (DE) 2023-04-19 EP disclosed
CN-115970062-A Bone cement-based drug sustained-release carrier and preparation method thereof 泽田(山东)药业有限公司 2023-04-18 CN disclosed
US-20210338166-A1 ENHANCED INGESTIBLE EVENT INDICATORS AND METHODS FOR MAKING AND USING THE SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-11-04 US disclosed
CN-112544609-A Cervical cell sample preservation solution and application thereof 广州市金圻睿生物科技有限责任公司 2021-03-26 CN disclosed
EP-3579706-B1 EDIBLE CONCENTRATE COMPRISING MICROFIBRILLATED CELLULOSE UNILEVER NV (NL) 2020-05-13 EP disclosed
WO-2018145886-A1 EDIBLE CONCENTRATE COMPRISING MICROFIBRILLATED CELLULOSE UNILEVER N.V. (NL) 2018-08-16 WO disclosed
US-20120164216-A1 PHARMACEUTICAL COMPOSITION OF DULOXETINE OR PHARMACEUTICALLY MATE SANJAY (IN) 2012-06-28 US disclosed
WO-2011121496-A1 COMPOSITION COMPRISING INSULIN AND HERBAL OIL FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION WOCKHARDT LIMITED (IN) 2011-10-06 WO disclosed
WO-2010150219-A1 PHARMACEUTICAL COMPOSITION OF DULOXETINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF WOCKHARDT RESEARCH CENTRE (IN) 2010-12-29 WO disclosed
US-20090250142-A1 Mg or Mg-Alloy Housing and Method for Producing the Same FUJITSU LIMITED (JP) 2009-10-08 US disclosed
US-20060054249-A1 Mg or Mg-alloy housing and method for producing the same FUJITSU LIMITED 2006-03-16 US disclosed
EP-0024032-B1 PHOSPHATE GLASS COMPOSITIONS, AND GLASS-CERAMIC MATERIALS, AND METHODS OF MAKING THE SAME FUJI PHOTO FILM CO., LTD. (JP) 1985-11-21 EP disclosed
US-4366253-A Phosphate glass compositions, and glass-ceramic materials, and methods of making the same FUJI PHOTO FILM CO., LTD. (JP) 1982-12-28 US disclosed
EP-0024032-A1 Phosphate glass compositions, and glass-ceramic materials, and methods of making the same FUJI PHOTO FILM CO., LTD. (JP) 1981-02-18 EP disclosed